articleThe Lancet Diabetes & EndocrinologyDec 17, 2020GREEN OA

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

University College London · The George Institute for Global Health · +14 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

526
total citations
FWCI
41.42
Percentile
100%
References
26
Citations per year

Authors

13

Topics & keywords

Keywords
  • Medicine
  • Dapagliflozin
  • Kidney disease
  • Diabetes mellitus
  • Adverse effect
  • Disease
  • Internal medicine
  • Benzhydryl compounds
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding